Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.

Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L.

Haematologica. 2019 Aug 14. pii: haematol.2018.203729. doi: 10.3324/haematol.2018.203729. [Epub ahead of print]

2.

Developing a Professional Identity as a Change Agent Early in Medical School: the Students' Voice.

McDermott C, Shank K, Shervinskie C, Gonzalo JD.

J Gen Intern Med. 2019 May;34(5):750-753. doi: 10.1007/s11606-019-04873-3.

PMID:
30783879
3.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. No abstract available.

4.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22. Erratum in: J Clin Invest. 2018 Oct 1;128(10):4743.

5.

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.

Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH.

Cancer Cell. 2018 Jan 8;33(1):44-59.e8. doi: 10.1016/j.ccell.2017.11.012. Epub 2017 Dec 21.

6.

Evaluation of Combined Extracorporeal Life Support and Continuous Renal Replacement Therapy on Hemodynamic Performance and Gaseous Microemboli Handling Ability in a Simulated Neonatal ECLS System.

Shank KR, Profeta E, Wang S, O'Connor C, Kunselman AR, Woitas K, Myers JL, Ündar A.

Artif Organs. 2018 Apr;42(4):365-376. doi: 10.1111/aor.12987. Epub 2017 Sep 21.

PMID:
28940550
7.

Evaluation of Hemodynamic Performance of a Combined ECLS and CRRT Circuit in Seven Positions With a Simulated Neonatal Patient.

Profeta E, Shank K, Wang S, O'Connor C, Kunselman AR, Woitas K, Myers JL, Ündar A.

Artif Organs. 2018 Feb;42(2):155-165. doi: 10.1111/aor.12907. Epub 2017 Jun 16.

PMID:
28621839
8.

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL.

Cancer Discov. 2017 May;7(5):494-505. doi: 10.1158/2159-8290.CD-16-1049. Epub 2017 Feb 13.

9.

Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells.

Kunimoto H, McKenney AS, Meydan C, Shank K, Nazir A, Rapaport F, Durham B, Garrett-Bakelman FE, Pronier E, Shih AH, Melnick A, Chaudhuri J, Levine RL.

Blood. 2017 Mar 30;129(13):1779-1790. doi: 10.1182/blood-2016-06-721977. Epub 2017 Jan 11.

10.

The Clinical Importance of Pulsatile Flow in Extracorporeal Life Support: The Penn State Health Approach.

Ündar A, Wang S, Izer JM, Clark JB, Kunselman AR, Patel S, Shank K, Profeta E, Wilson RP, Ostadal P.

Artif Organs. 2016 Dec;40(12):1101-1104. doi: 10.1111/aor.12875. No abstract available.

PMID:
27911024
11.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

12.

Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.

Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, Martinez AB, Rivera SA, Durham BH, Rapaport F, Keller MD, Pandey S, Bastian L, Tovbin D, Weinstein AR, Teruya-Feldstein J, Abdel-Wahab O, Santini V, Mason CE, Melnick AM, Mukherjee S, Levine RL.

Leukemia. 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358. Epub 2015 Dec 29.

13.

Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis.

Viny AD, Ott CJ, Spitzer B, Rivas M, Meydan C, Papalexi E, Yelin D, Shank K, Reyes J, Chiu A, Romin Y, Boyko V, Thota S, Maciejewski JP, Melnick A, Bradner JE, Levine RL.

J Exp Med. 2015 Oct 19;212(11):1819-32. doi: 10.1084/jem.20151317. Epub 2015 Oct 5.

14.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL.

Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

15.

Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer SD, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine RL.

Cancer Cell. 2015 Apr 13;27(4):502-15. doi: 10.1016/j.ccell.2015.03.009.

16.

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL.

Blood. 2014 Mar 27;123(13):2075-83. doi: 10.1182/blood-2014-01-547760. Epub 2014 Jan 27.

17.

Feasibility and effects of preventive home visits for at-risk older people: design of a randomized controlled trial.

Cutchin MP, Coppola S, Talley V, Svihula J, Catellier D, Shank KH.

BMC Geriatr. 2009 Dec 3;9:54. doi: 10.1186/1471-2318-9-54.

18.

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Calcagno JA, Eki C, Harris KA, Joyave J, McFarland K, Protter P, Sullivan M, Stanford A, Lovett N, Ortiz M, Rojas S, Cyrus S, Cyrus J, Cohen S, Buchin D, Riordan L, Zuniga M, Shah R, Minard C, Quintin A, Douglas G, van Houten J, Freutner S, Chartrand S, Nowatzke P, Romero J, Rhodes T, Benoit M, Walter E, Walker L, DeBonnett L, Cross M, Free T, Martin S, Shank K, Guedes B, Atkinson LA, Halpin GJ, Rouse K, Hand I, Geiss D, Marshall JR, Burleson L, Boland J, Seybold K, Hunter V, Unfer S, Schmucker J, Gley M, Marcus M, Thompson P, Milla P, Young C, Zanni R, Zinno V, Fetter-Zarzeka A, Busey A, Sokunbi MA, Airington S, Richard N, Muraligopal V, Lewis S, Weber FT, Giordano BP, Linehan D, Roach J, Davis R, Rzepka AA, Booth T, Smeltzer D, Walsh J, Arispe E, Rowley R, Bolling C, Botts T, Haskett K, Raby D, Batiz E, Gelfand A, Farrell L, Butler S, Colby L, Schochet P, Bentler J, Hirsch D, Wilkinson L, Aaronson A, Bennett E, Wingate J, Quinn D, Komendowski K, Deckard M, Frogel M, Nerwen C, Copenhaver S, Prater M, Wolsztein J, Mackey K, Benbow M, Naranjo M, Hensley S, Hayes C, Sadeghi H, Lawson SM, McCall M, Combs K, Ledbetter J, Sarnosky K, Swafford C, Speer M, Barton WJ, Mink JW, Lemm D, Hudak M, Case E, Rowen J, Fuentes S, Pane C, Richardson L, Chavarria C, Cassino D, Ghaffari K, Carroll C, Lee H, Guclu L, Johnson C, Blum V, Boron ML, Sorrentino M, Hirsch RL, Van Veldhuisen PC, Smith C; Palivizumab Outcomes Registry Study Group.

Pediatr Pulmonol. 2003 Jun;35(6):484-9.

PMID:
12746948
19.

Induction of lipid metabolic enzymes during the endoplasmic reticulum stress response in plants.

Shank KJ, Su P, Brglez I, Boss WF, Dewey RE, Boston RS.

Plant Physiol. 2001 May;126(1):267-77.

20.

Descriptive epidemiology of captive cervid herds in Michigan, USA.

Bruning-Fann CS, Shank KL, Kaneene JB.

Vet Res. 1997 May-Jun;28(3):295-302.

PMID:
9208449
21.

Unexpected neurotoxicity in dogs receiving a cyclophosphamide, dactinomycin, and 5-fluorouracil chemotherapy protocol.

Hammer AS, Carothers MA, Harris CL, O'Keefe DA, Ayl RD, Peterson JL, Shank KA, Couto CG.

J Vet Intern Med. 1994 May-Jun;8(3):240-3.

22.

Treatment of tumor-bearing dogs with actinomycin D.

Hammer AS, Couto CG, Ayl RD, Shank KA.

J Vet Intern Med. 1994 May-Jun;8(3):236-9.

23.

Goodwin House, a place for healing.

Shank K.

Inter Des. 1992 Dec;63(16):20-1.

PMID:
10123166
24.

Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma.

Hammer AS, Couto CG, Filppi J, Getzy D, Shank K.

J Vet Intern Med. 1991 May-Jun;5(3):160-6.

26.

The role of the health physicist in the development of safe energy sources.

Turner JE, Shank KE, Loebl AS, Easterly CE.

Health Phys. 1978 Feb;34(2):189-90. No abstract available.

PMID:
632099
27.

A mathematical model of cadmium transport in a biological system.

Shank KE, Vetter RJ, Ziemer PL.

Environ Res. 1977 Apr;13(2):209-14. No abstract available.

PMID:
862593
28.

Uptake and distribution of cadmium in mice following repeated administrations.

Shank KE, Vetter RJ, Ziemer PL.

Arch Environ Contam Toxicol. 1977;6(1):63-8.

PMID:
907376
29.

The effects of copper, mercury, and zinc on the uptake and distribution of cadmium-115 m in the albino rat.

Shank KE, Vetter RJ.

Environ Lett. 1974;6(1):13-8. No abstract available.

PMID:
4814577
30.

RECOGNITION OF ARTICULATORY DISORDERS IN CHILDREN.

SHANK KH.

Clin Pediatr (Phila). 1964 Jun;3:333-4. No abstract available.

PMID:
14154322
31.

Environmental factors in relation to the speech of cerebral palsied children.

HOOD PN, SHANK KH, WILLIAMSON DB.

J Speech Disord. 1948 Dec;13(4):325-31. No abstract available.

PMID:
18105497

Supplemental Content

Support Center